MedTrace Logo

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

NCT00195338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2012-01-23

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.

Conditions

Interventions

DRUG

etanercept

Sponsors & Collaborators

  • Innovex, Inc

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195338 on ClinicalTrials.gov